Achilles Therapeutics plc (ACHL) News
Filter ACHL News Items
ACHL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest ACHL News From Around the Web
Below are the latest news stories about ACHILLES THERAPEUTICS PLC that investors may wish to consider to help them evaluate ACHL as an investment opportunity.
Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights– On track to dose 15-20 patients with higher dose cNeT by year-end 2023 – – Clinical and translational science data update from the ongoing Phase I/IIa trials in NSCLC and melanoma expected in Q1 2024 with additional data available in mid-2024 – – Strong cash position of $140 million supports operations through 2025 – LONDON, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies tar |
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An AnalysisNEW YORK, NY / ACCESSWIRE / October 24, 2023 / The biotech sector, known for its exponential growth potential, is currently facing highly challenging market conditions. Influences like rising inflation, geopolitical tensions, and looming economic ... |
Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement- Achilles ADSs will continue to trade on the Nasdaq Global Select Market at this time, and the Company’s operations are not affected by the receipt of the Notice -LONDON, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today disclosed that the Company received notice on September 20, 2023 from the Nasdaq Stock Market LLC (“N |
Are Medical Stocks Lagging Achilles Therapeutics (ACHL) This Year?Here is how Achilles Therapeutics PLC Sponsored ADR (ACHL) and HealthEquity (HQY) have performed compared to their sector so far this year. |
Waters (WAT) Walk-Up Solutions Boost Bioprocess DevelopmentWaters (WAT) launches new bioprocess walk-up solutions, automating sample prep and analysis from any bioreactor. |
Is KalVista Pharmaceuticals (KALV) Stock Outpacing Its Medical Peers This Year?Here is how KalVista Pharmaceuticals, Inc. (KALV) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year. |
Jazz (JAZZ) Beats on Q2 Earnings & Sales, Raises '23 ViewJazz (JAZZ) reports better-than-expected second-quarter results as earnings and sales beat expectations. The company raises its financial guidance for 2023. |
Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights- Clinical and translational science data expected in the fourth quarter of 2023 from the ongoing Phase I/IIa trials in NSCLC and melanoma - - neoRanker™ immunogenicity prediction module of PELEUS™ increases the likelihood of identifying multiple memory T cell responses - - Strong cash position of $144 million supports operations through 2025 - LONDON, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered prec |
Achilles Therapeutics to Present at Upcoming ConferencesLONDON, June 12, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced that the Company will be taking part in the following conferences in June: SAE Media Group Inaugural Cell and Gene Therapy Conference, London, United Kingdom Sergio Quezada, PhD, Chief Scientific Officer, will give an oral presentation titled “Targeting Clonal Neoantigens in Cancer” o |